The ASCO Annual Meeting was held from 3–7 June 2022 in a live and virtual format. During this Meeting, de-escalation and intensifying strategies were shown in different stages of nasopharyngeal carcinoma (NPC) and head and neck squamous cell carcinoma (HNSCC). More data were presented regarding radiosensitising options during adjuvant/definitive radiotherapy. The position of immunotherapy in relation to radiotherapy remains a big question anno 2022. New first-line recurrent/metastatic treatment options of combining immunotherapy and a tyrosine kinase inhibitor are on the horizon, and also the liquid biopsy technology is of high interest in the field of HNSCC. Supportive care of severe oral mucositis was addressed with a new product. Targeted therapy and immunotherapy are looking for their exact place in salivary gland tumours. In this report, the most important headlines will be discussed, with comments on the clinical relevance of the different studies.
(Belg J Med Oncol 2022;16(5):236–45)